NCT02212925View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 14332 CL as Tablet in Female and Male Patients With Type 2 Diabetes

PHASE1TerminatedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

March 31, 2007

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

BI 14332 CL

DRUG

Placebo

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02212925 - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 14332 CL as Tablet in Female and Male Patients With Type 2 Diabetes | Biotech Hunter | Biotech Hunter